Mutated EGFR-IN-1

CAS No. 1421372-66-8

Mutated EGFR-IN-1( Osimertinib analog )

Catalog No. M23574 CAS No. 1421372-66-8

Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 48 In Stock
50MG 55 In Stock
100MG 74 In Stock
200MG 106 In Stock
500MG 177 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Mutated EGFR-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
  • Description
    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Osimertinib analog
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR (L858R)|EGFR (T790M)|EGFR(Exon 19 deletion/T790M)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1421372-66-8
  • Formula Weight
    445.56
  • Molecular Formula
    C25H31N7O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 75 mg/mL (168.33 mM)
  • SMILES
    NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Patent WO 2013014448 A2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer .
molnova catalog
related products
  • XL-647

    XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.

  • Epertinib

    Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.

  • Cimigenoside

    Cimigenoside is an active compound from genus Cimicifuga.